The National Institute for Health and Care Excellence

Thousands eligible for new chronic heart failure treatment following NICE recommendation

Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our ...
National Institute for Health and Care Excellence

Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)

NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen (PSMA)-positive hormone-relapsed metastatic prostate cancer in ...
National Institute for Health and Care Excellence

Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

There is a commercial access agreement for daratumumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact jnj_imukcs@its.jnj.com ...
National Institute for Health and Care Excellence

People and communities - putting you at the heart of our work

There are different ways to get involved in NICE’s work and help us to improve NHS and care services for other people – either those who are like you, or those communities you represent as part of a ...
National Institute for Health and Care Excellence

Browse guidance by topic

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...